MT-1-online

MT-1-online (Melanotan I / Afamelanotide)

1. Overview

MT-1, commonly associated with Melanotan I, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It acts primarily on melanocortin-1 receptors (MC1R), stimulating melanocytes to produce eumelanin, the brown-black pigment responsible for much of the skin’s natural pigmentation. Because of this mechanism, MT-1 has been investigated for its ability to increase pigmentation and provide greater protection of skin cells from light exposure.

It is important to distinguish research-grade products marketed online as “Melanotan I” from afamelanotide, the regulated pharmaceutical form. Afamelanotide is an approved medicine in the United States and European Union for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare condition that causes painful reactions to light. (FDA Access Data)

2. Mechanism of Action

MT-1-online mimics the activity of α-MSH by stimulating MC1R. This increases melanin production in melanocytes and can result in increased skin pigmentation. The resulting eumelanin absorbs some ultraviolet and visible radiation, helping reduce light penetration into the skin. In EPP, this mechanism helps decrease painful phototoxic reactions. (FDA Access Data)

3. Uses and Research Applications

MT-1-online related compounds have been investigated for several applications, including:

• Pigmentation research: Studying the biological mechanisms responsible for melanin production.
• Photosensitivity disorders: Investigating whether increased eumelanin can reduce reactions to sunlight.
• Erythropoietic protoporphyria: Afamelanotide is clinically used to increase pain-free light exposure in adults with EPP. (FDA Access Data)
• Photoprotection research: Examining the potential protective effects of increased melanin against light-induced cellular damage.
• Dermatological research: Investigating melanocortin receptors and their effects on skin pigmentation.

4. Mode of Usage

The approved pharmaceutical form, afamelanotide (SCENESSE), is administered as a subcutaneous implant by a trained healthcare professional. The FDA-approved product contains 16 mg and is administered approximately every two months for its approved EPP indication. (FDA Access Data)

Online products labelled “MT-1” or “Melanotan I” may instead be unapproved research products. There is no established or approved self-administration regimen for these products, so specific injection doses, reconstitution instructions, or tanning protocols should not be assumed from online product descriptions. Using an unregulated injectable product also introduces concerns about purity, sterility, contamination, and incorrect concentration.

5. Safety and Regulatory Considerations

Potential adverse effects associated with melanocortin agonist therapy can include nausea, headache, flushing, fatigue, and changes in pigmentation. Changes in existing moles or freckles should be medically evaluated. Importantly, increased pigmentation does not eliminate the need for appropriate sun protection.

6. Conclusion

MT-1-online is a melanocortin-based compound primarily associated with stimulation of melanin production. Its most established medical application is through afamelanotide, which is used under medical supervision for adults with EPP. Although online products may be marketed for cosmetic tanning or pigmentation, these products should not be confused with approved pharmaceutical afamelanotide, and their safety and quality may not be established.